ArticleDisease models & mechanisms2026
Tumor-suppressive activities of SA1/STAG2 and effects of PARP impairment during brain development.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The cohesin complex performs essential cellular functions including regulation of chromatin organization and DNA repair. Somatic pathogenetic variants in cohesin genes, such as STAG2, have been associated with cancer, but their contribution to brain tumorigenesis is unclear. Here, we report the presence of STAG2 variants in patients with glioblastoma and medulloblastoma and determined the effects of loss of STAG2 in human cells and of the homolog SA1 in Drosophila tissues. Reduction of SA1 expression during fly brain development led to defects in neural stem cell differentiation and promotion of tumorigenesis, both in the presence and absence of oncogenic activity. Treatment with inhibitors of poly ADP-ribose polymerase (PARP), which are used to treat forms of cancer with defects in DNA repair, in combination with STAG2/SA1 depletion resulted in apoptosis in vitro and in vivo. In flies, reduction of PARP activity ameliorated the tumor-associated phenotypes of SA1-deficient tissue. Our in vivo and in vitro data suggest that impairment of PARP activity compensates for reduced cohesin activity, highlighting a vulnerability that could be pharmacologically exploited in brain tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.